Cetera Investment Advisers
RXRX icon

Cetera Investment Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

Cetera Investment Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453K Sell
123,380
-4,315
-3% -$14.4K ﹤0.01% 3793
2026
Q1 		$392K Sell
127,695
-1,309
-1% -$5.06K ﹤0.01% 3738
2025
Q4 		$528K Buy
129,004
+1,582
+1% +$7.84K ﹤0.01% 3387
2025
Q3 		$622K Buy
127,422
+33,145
+35% +$174K ﹤0.01% 3205
2025
Q2 		$477K Buy
94,277
+18,489
+24% +$90.8K ﹤0.01% 3007
2025
Q1 		$401K Buy
75,788
+13,955
+23% +$102K ﹤0.01% 3033
2024
Q4 		$418K Buy
61,833
+13,751
+29% +$92.5K ﹤0.01% 2819
2024
Q3 		$317K Sell
48,082
-3,107
-6% -$22.3K ﹤0.01% 3019
2024
Q2 		$384K Buy
51,189
+4,896
+11% +$42.7K ﹤0.01% 2804
2024
Q1 		$462K Buy
46,293
+33,521
+262% +$373K ﹤0.01% 2661
2023
Q4 		$126K Buy
+12,772
New +$91.1K ﹤0.01% 2119

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cetera Investment Advisers's RXRX Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Recursion Pharmaceuticals (RXRX) stake by 3.4% in Q2 2026, selling an estimated $14.4K and leaving 123,380 shares worth $453K. The position accounts for ﹤0.01% of the portfolio, ranked #3793.

Cetera Investment Advisers first reported a position in RXRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $622K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Cetera Investment Advisers held 123,380 shares of Recursion Pharmaceuticals worth $453K as of Q2 2026.
  • Cetera Investment Advisers sold 4,315 Recursion Pharmaceuticals shares in Q2 2026, an estimated $14.4K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #3793 holding.
  • Cetera Investment Advisers first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Cetera Investment Advisers's Recursion Pharmaceuticals position peaked at $622K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.